New Haven biotech Alexion Pharmaceuticals Inc. will partner with a startup in the Netherlands on a new drug to treat degenerative brain disorders. Alexion on Monday announced a deal with ...

An AstraZeneca drug acquired in a $930 million deal has received FDA approval as a treatment for a rare blood disorder. In this disease, paroxysmal nocturnal hemoglobinuria (PNH), a part of the immune ...

Novartis has filed suit against AstraZeneca’s rare disease unit, claiming that certain marketing materials for Alexion’s Ultomiris create an inaccurate impression of Novartis’ rival drug Fabhalta.

Alexion's innovative approach to complement inhibition has received some of the pharmaceutical industry's highest honors: the 2008 Prix Galien USA Award for Best Biotechnology Product with broad ...